Several antibiotic drug developers are looking to alternative delivery systems to offer localized delivery for anti-infective agents – such as inhaled formulations that target the lungs – a pathway that could result in new approvals for older molecules.
Pulmonary delivery technology that could make new products from generic antibiotics has attracted a range of respiratory-focused companies to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?